Biomedical · global
Using Melanoma’s Mutation Pathway as a Delivery Address, DYP688 Phase 1 Trial Shows Early Signals
Uveal melanoma has long lacked effective drug options; a new therapy combining a PMEL antibody, ADC delivery, and a Gq/11 inhibitor shrank some tumors in an early human trial, but it still has a clinical road ahead before proving it can prolong life.
For patients with metastatic uveal melanoma, the treatment challenge lies not only in the fact that cancer cells have spread, but also in the difficulty of precisely suppressing its common driver mutations with traditional drugs. Phase 1 clinical data for DYP688, recently published in Nature Medicine, offers a new direction for the field: not simply searching for tumor surface markers, and not only designing a signal inhibitor, but linking the two together in an attempt to deliver a drug directly into melanoma cells with specific biological characteristics.
DYP688 is a PMEL-targeting antibody-drug conjugate carrying a payload that can inhibit Gq/11 signaling. GNAQ and GNA11 mutations are common molecular events in uveal melanoma and drive downstream signal activation; PMEL is a melanocyte lineage-associated protein. The core of this design is to use the lineage features of melanoma cells as an entry point, then bring a drug targeting the mutant signaling axis into the tumor environment.
According to the Nature Medicine report, this early trial treated 66 patients, covering metastatic uveal melanoma and other melanomas with GNAQ/GNA11 mutations. The overall objective response rate was 19.7%, 71.2% of patients had tumor shrinkage, and the rate of grade 3 treatment-related adverse events was 7.6%. These figures show that DYP688 has produced a signal of antitumor activity, but the main task of a phase 1 study remains exploring safety, dose, and preliminary efficacy, and it cannot be directly equated with proven clinical benefit.
Clinical trial registration data provides the study framework. ClinicalTrials.gov describes NCT05415072 as a first-in-human, open-label, multicenter phase 1/2 trial sponsored by Novartis Pharmaceuticals, studying single-agent DYP688 in metastatic uveal melanoma and other GNAQ/11-mutant melanomas; its registration status is active, not recruiting, and the registration page had not posted results at the time. The U.S. National Cancer Institute trial page states that the study has stopped recruiting and explains that the trial objectives include evaluating safety, tolerability, and antitumor activity, with a design that includes dose escalation and subsequent phase 2 groups.
Earlier data from the same study had previously been disclosed in conference abstract form. A 2025 ASCO abstract recorded in the Western Sydney Local Health District digital repository stated that, as of October 25, 2024, among 66 participants, 60 had metastatic uveal melanoma and 6 had non-uveal melanoma; among 55 patients who received at least 8 mg/kg once every two weeks and were evaluable by RECIST, 12 had confirmed objective responses and another 35 had stable disease. The abstract also stated that no treatment discontinuations due to adverse events had been seen at that time. These data are consistent with the direction of the formal paper, but the details should still be based on the full peer-reviewed paper.
This result is notable because drug development for metastatic uveal melanoma is often constrained on two levels: on one hand, it differs from cutaneous melanoma in molecular drivers and immune response; on the other hand, even knowing that GNAQ/GNA11 mutations are important, translating this signaling axis into an effective and tolerable treatment is not easy. DYP688 proposes a “biology-matched” strategy, attempting to make tumor lineage markers, mutant signaling, and drug delivery fit together.
However, an early response rate is not the endpoint. The more critical questions ahead include how long responses can be maintained, whether progression-free survival or overall survival can be improved, which patients are most likely to benefit, and whether the ADC payload and target expression will bring cumulative toxicity or resistance. The phase 2 group design mentioned on the NCI page includes patients with metastatic uveal melanoma who have and have not received tebentafusp treatment; only when subsequent data mature will there be a chance to see clearly where DYP688 belongs in the existing treatment sequence.